[Source: Antimicrobial Agents and Chemotherapy, full page: (LINK). Abstract, edited.]
Activity of imipenem/relebactam against a large collection of Pseudomonas aeruginosa clinical isolates and isogenic β-lactam resistant mutants
Pablo Fraile-Ribot, Laura Zamorano, Rocío Orellana, Ester del Barrio-Tofiño, Irina Sánchez-Diener, Sara Cortes-Lara, Carla López-Causapé, Gabriel Cabot, Germán Bou, Luis Martínez-Martínez, Antonio Oliver, and on behalf of GEMARA-SEIMC/REIPI Pseudomonas study Group
Imipenem and Imipenem/relebactam MICs were determined for 1,445 P. aeruginosa clinical isolates and a large panel of isogenic mutants showing the most relevant mutation-driven β-lactam resistance mechanisms. Imipenem/relebactam showed highest susceptibility rates (97.3%), followed by colistin and ceftolozane/tazobactam (both 94.6%). Imipenem/relebactam MICs remained ≤2 μg/mL in all 16 isogenic PAO1 mutants and in 8 pairs of XDR clinical strains that had developed resistance to ceftolozane/tazobactam and ceftazidime/avibactam due to mutations in OXA-10 or AmpC.
Copyright © 2019 American Society for Microbiology. All Rights Reserved.
Keywords: Antibiotics; Drugs Resistance; Pseudomonas aeruginosa; Imipenem; Relebactam.